TVGNHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Tevogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TVGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Mar 2026 | D. Boral Capital | Downgrade | Hold | — |
| 3 Mar 2026 | D. Boral Capital | Maintains | Buy | $5.00 → $2.00 |
| 20 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2025 | D. Boral Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVGN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 96% of US stocks
Cheaper than 72% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tevogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Tevogen Bio Holdings Inc. announced it will change its corporate name to Tevogen Inc., following approval by its Board of Directors. The company will operate under the new name effective immediately.
Why it matters — A name change can signal a shift in corporate identity or strategy, and shareholders will need to be aware of the new legal name for filings and communications.
Of the 1 analysts covering Tevogen, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tevogen, Inc. 15 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Tevogen, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No analyst covering Tevogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVGN are extrapolating price history, which says nothing about the business.
Tevogen, Inc. returned -85.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies using its ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders.
The most recent item we track (GlobeNewsWire, 29 July 2026): "Tevogen Bio Holdings Inc. Becomes Tevogen Inc.". Tevogen Bio Holdings Inc. announced it will change its corporate name to Tevogen Inc., following approval by its Board of Directors. The company will operate under the new name effective immediately.
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies using its ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders. The company targets antigens present only on diseased cells to spare healthy tissue, enhancing safety through naturally occurring T cell receptors, with applications spanning oncology, neurology, and virology. Key product candidates include TVGN 489, which has completed Phase 1 trials for high-risk COVID-19 patients and is in Phase 1 for acute SARS-CoV-2 in B-cell suppressed individuals and Long COVID; TVGN 920 and TVGN 960 in preclinical stages for cervical and oropharyngeal cancers; TVGN 601 for multiple sclerosis; TVGN 930 for Epstein-Barr virus-associated lymphomas; and TVGN 116 for hepatitis B. Tevogen Bio Holdings Inc. also advances Tevogen.AI, applying proprietary predictive technologies like PredicTcell™ to accelerate drug development through immunologically active peptide identification. Founded in 2020 and headquartered in Warren, New Jersey, the company focuses on making therapies commercially viable and accessible to broad patient populations in the biotechnology sector.
CEO Dr. Ryan H. Saadi M.D., M.P.H. · 18 employees · United States · https://tevogen.com